EGFR T790M resistance mutation in non small-cell lung carcinoma

被引：59

作者：

Denis, Marc G. ^{[1
]}

Vallee, Audrey ^{[1
]}

Theoleyre, Sandrine ^{[1
]}

机构：

[1] Nantes Univ Hosp, Dept Biochem, Nantes, France

来源：

CLINICA CHIMICA ACTA | 2015年 / 444卷

关键词：

EGFR; T790M; Mutation; Resistance; Non small-cell lung cancer; FACTOR RECEPTOR MUTATIONS; RESOLUTION MELTING ANALYSIS; TYROSINE KINASE INHIBITORS; OPEN-LABEL; 1ST-LINE TREATMENT; ACQUIRED-RESISTANCE; SEQUENCE ARTIFACTS; DRUG-RESISTANCE; CANCER PATIENTS; NEVER-SMOKERS;

D O I：

10.1016/j.cca.2015.01.039

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Lung cancer patients carrying sensitive epidermal growth factor receptor (EGFR) mutations show dramatic responses to tyrosine kinase inhibitors (TKIs). However, the majority of patients whose disease responds to drugs eventually develop resistance to these EGFR-TKIs. The T790M gatekeeper mutation in the EGFR tyrosine kinase domain accounts for half of resistance to these drugs. In some patients, this mutation is also detected as a primary event before drug exposure, at a frequency that is highly dependent on the technique used. This review will focus on the methods that have been used to detect the T790M mutation, and its potential clinical applications both in TKI naive patients and in patients with an acquired resistance. (C) 2015 Elsevier B.V. All rights reserved.

引用

页码：81 / 85

页数：5

共 67 条

[1] EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics [J].

Arcila, Maria E. ;

Nafa, Khedoudja ;

Chaft, Jamie E. ;

Rekhtman, Natasha ;

Lau, Christopher ;

Reva, Boris A. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :220-229

[2] Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network [J].

Beau-Faller, M. ;

Prim, N. ;

Ruppert, A. -M. ;

Nanni-Metellus, I. ;

Lacave, R. ;

Lacroix, L. ;

Escande, F. ;

Lizard, S. ;

Pretet, J. -L ;

Rouquette, I. ;

de Cremoux, P. ;

Solassol, J. ;

de Fraipont, F. ;

Bieche, I. ;

Cayre, A. ;

Favre-Guillevin, E. ;

Tomasini, P. ;

Wislez, M. ;

Besse, B. ;

Legrain, M. ;

Voegeli, A. -C. ;

Baudrin, L. ;

Morin, F. ;

Zalcman, G. ;

Quoix, E. ;

Blons, H. ;

Cadranel, J. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :126-131

[3] Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR [J].

Bell, DW ;

Gore, I ;

Okimoto, RA ;

Godin-Heymann, N ;

Sordella, R ;

Mulloy, R ;

Sharma, SV ;

Brannigan, BW ;

Mohapatra, G ;

Settleman, J ;

Haber, DA .

NATURE GENETICS, 2005, 37 (12) :1315-1316

[4] The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial [J].

Costa, Carlota ;

Molina, Miguel Angel ;

Drozdowskyj, Ana ;

Gimenez-Capitan, Ana ;

Bertran-Alamillo, Jordi ;

Karachaliou, Niki ;

Gervais, Radj ;

Massuti, Bartomeu ;

Wei, Jia ;

Moran, Teresa ;

Majem, Margarita ;

Felip, Enriqueta ;

Carcereny, Enric ;

Garcia-Campelo, Rosario ;

Viteri, Santiago ;

Taron, Miquel ;

Ono, Mayumi ;

Giannikopoulos, Petros ;

Bivona, Trever ;

Rosell, Rafael .

CLINICAL CANCER RESEARCH, 2014, 20 (07) :2001-2010

[5] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].

Cross, Darren A. E. ;

Ashton, Susan E. ;

Ghiorghiu, Serban ;

Eberlein, Cath ;

Nebhan, Caroline A. ;

Spitzler, Paula J. ;

Orme, Jonathon P. ;

Finlay, M. Raymond V. ;

Ward, Richard A. ;

Mellor, Martine J. ;

Hughes, Gareth ;

Rahi, Amar ;

Jacobs, Vivien N. ;

Brewer, Monica Red ;

Ichihara, Eiki ;

Sun, Jing ;

Jin, Hailing ;

Ballard, Peter ;

Al-Kadhimi, Katherine ;

Rowlinson, Rachel ;

Klinowska, Teresa ;

Richmond, Graham H. P. ;

Cantarini, Mireille ;

Kim, Dong-Wan ;

Ranson, Malcolm R. ;

Pao, William .

CANCER DISCOVERY, 2014, 4 (09) :1046-1061

[6] Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples [J].

Didelot, Audrey ;

Le Corre, Delphine ;

Luscan, Armelle ;

Cazes, Aurelie ;

Pallier, Karine ;

Emile, Jean-Francois ;

Laurent-Puig, Pierre ;

Blons, Helene .

EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2012, 92 (03) :275-280

[7] Sequence Artifacts in DNA from Formalin-Fixed Tissues: Causes and Strategies for Minimization [J].

Do, Hongdo ;

Dobrovic, Alexander .

CLINICAL CHEMISTRY, 2015, 61 (01) :64-71

[8]

Do HD, 2012, ONCOTARGET, V3, P546

[9] High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies [J].

Do, Hongdo ;

Krypuy, Michael ;

Mitchell, Paul L. ;

Fox, Stephen B. ;

Dobrovic, Alexander .

BMC CANCER, 2008, 8 (1)

[10] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study [J].

Douillard, J-Y ;

Ostoros, G. ;

Cobo, M. ;

Ciuleanu, T. ;

McCormack, R. ;

Webster, A. ;

Milenkova, T. .

BRITISH JOURNAL OF CANCER, 2014, 110 (01) :55-62

← 1 2 3 4 5 6 7 →